Genetic Markers in Advanced Prostate Cancer Could Explain Treatment Resistance

Genetic Markers in Advanced Prostate Cancer Could Explain Treatment Resistance
Researchers at the Mayo Clinic Center for Individualized Medicine have identified genetic markers that can predict resistance to Zytiga (abiraterone acetate) and prednisone in patients with metastatic castration-resistant prostate cancer. The new findings could enable healthcare providers to identify in advance patients who will not respond to the treatment, to select a more effective approach. The study, “A Prospective Genome-Wide Study of Prostate Cancer Metastases Reveals Association of Wnt Pathway Activation and Increased Cell Cycle Proliferation with Primary Resistance to Abiraterone Acetate-Prednisone,” appeared in the journal Annals of Oncology. The research, conducted between 2013 and 2015, was led by Manish Kohli, MD, and Liewei Wang, MD, PhD. The results revealed genetic markers that may predict resistance to Zytiga and prednisone, which aim to stop progression of advanced, metastatic prostate cancer. Prostate cancer currently affects approximately one in seven men in the U.S., 10-20% of whom ultimately develop castration-resistant prostate cancer, which does not respond to standard hormone treatment. These patients’ average life expectancy is less than 19 months. The scientists conducted molecular biology experiments analyzing DNA to study all disease-causing genes and RNA to specifically analyze the levels of each individual gene. The experiments were per
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *